International Speakers

Prof Peter Goldstraw

Peter Goldstraw is Honorary Consultant in Thoracic Surgery to the Royal Brompton Hospital and Emeritus Professor of Thoracic Surgery at the National Heart and Lung Institute, Imperial College, London, UK. He has given 400 lectures at International and National conferences. He received the Price Thomas Gold Medal from the Royal College of Surgeons of England in 2004, awarded triennially in recognition of meritorious contributions in surgery. He has been honoured with a Lifetime Achievement Award by the British Thoracic Oncology Group in 2006 and the Society for Cardiothoracic Surgery in Great Britain and Ireland in 2010. He received honorary membership of the ESTS in 2007 and the Merit Award by the IASLC in 2007 He has published over 280 peer-reviewed articles and 55 chapters in specialist textbooks. He co-edited the Lung and Pleural Tumours chapter of the UICC 7^th Edition of TNM and was executive editor for the Staging Handbook and Manual in Thoracic Oncology published by the IASLC/UICC/AJCC. He chaired the IASLC Staging Project from its inception in 1998 until the publication of the 7^th edition of TNM in 2009. He is a board member and President of the International Association for the Study of Lung Cancer.

Liz Darlison

Macmillan Consultant Nurse, Mesothelioma UK
The University Hospitals of Leicester

Liz Darlison trained at Charles Frears School of Nursing in Leicester qualifying in 1986. Since 1992 she has been based within the cardio-respiratory directorate of the University Hospitals of Leicester at the Glenfield Hospital site. 

Liz was a ward sister/manager in respiratory for several years and in June 2000 she took up the post of Respiratory Nurse Specialist (Lung Cancer). Liz’s interests within lung cancer have always focused on developing the nursing contribution, within the multidisciplinary team, to improve patient and carer experience across the whole cancer pathway. 

To meet demand locally and nationally Liz developed an interest in Mesothelioma which resulted in the establishment of Mesothelioma UK, the National Macmillan Mesothelioma Resource Centre. Liz is currently a Consultant Nurse and clinical lead for Mesothelioma UK which has established itself as an essential part of the UK Mesothelioma landscape; a centre of excellence providing mesothelioma information, support and education.  

In recognition of Mesothelioma UK’s early success in 2007 Liz was awarded the Nursing Times Cancer Nurse Leader of the Year Award sponsored by the Royal Marsden NHS Foundation Trust. 

Liz is an Honorary Senior Lecturer at the DeMontfort University, Leicester and Honorary Lecturer at the Royal Marsden School of Cancer Nursing and Rehabilitation. 

Liz is a committee member of the National Lung Cancer Forum for Nurses and the British Thoracic Oncology Group. She represents nursing on a variety of national and professional committees and is proud to be a founding member of the International Thoracic Oncology Nursing Forum.

Pasi A. Jänne, MD, PhD

Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute, Boston

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He currently works in the Lowe Center for Thoracic Oncology at DFCI. His main research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents

Dr. Jänne is proudly sponsored by:  

Federico Cappuzzo, MD, PhD

Director of Medical Oncology
OspedaleCivile in Livorno, Italy

Federico Cappuzzo, MD, is a Professor and Director of the Department of Medical Oncology at OspedaleRiuniti in Livorno, Italy. His main fields of interests include the treatment of lung cancer and colorectal cancer. Dr.Cappuzzo is involved in the development of new drugs such as irreversible tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC), leading to over 50 publications in peer reviewed journals. He discovered one of the most relevant mechanisms responsible for sensitivity to erlotinib and gefitinib in NSCLC (EGFR FISH testing), as well as the mechanism responsible for sensitivity to cetuximab in colorectal cancer (EGFR FISH testing). Dr.Cappuzzo is involved in several translational research studies looking at the mechanisms of resistance and sensitivity to targeted therapy. He has been involved in numerous clinical trials for newly developed therapeutic agents.

Dr.Cappuzzo is proudly sponsored by:

Mark G. Kris, MD 

Chief, Thoracic Oncology Service
The William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College

Dr Mark Kris is a medical oncologist who specialises in the care of persons with cancers arising in the chest: including lung cancer, thymoma, mediastinal tumors, and cancer of unknown primary site. Research interests include tests for new anticancer treatments, the discovery of medicines that specifically attack lung cancer, multimodality therapy (using surgery, radiotherapy, and chemotherapy together to destroy cancers), and better ways to control physical symptoms caused by cancer and cancer treatment. Dr Kris is particularly interested in finding ways to select the best treatments for persons with cancer based on clinical factors and the molecular characteristics of their tumor specimens.

Dr. Kris is proudly sponsored by: